Thrombin generation in children with sickle cell disease: Relationship with age, hemolysis, transcranial doppler velocity, and hydroxyurea treatment

European Journal of Haematology

Volumn 91, Issue 1, 2013, Pages 46-54

  Noubouossie, Denis C F ^a   Lê, Phu Q ^b   Rozen, Laurence ^a   Ziereisen, France ^b   Willems, Dominique ^a   Demulder, Anne ^a   Ferster, Alina ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Coagulation; Hemolysis; Hydroxyurea; Sickle; Thrombin generation; Transcranial Doppler

Indexed keywords

HYDROXYUREA; PHOSPHOLIPID; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; CHILD; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; GROUPS BY AGE; HEMOLYSIS; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEMBRANE MICROPARTICLE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; THROMBOCYTE POOR PLASMA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANEMIA, SICKLE CELL; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMOGLOBINS; HEMOLYSIS; HOMOZYGOTE; HUMANS; HYDROXYUREA; MALE; PHOSPHOLIPIDS; PLASMA; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; YOUNG ADULT;

EID: 84879461503     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12113     Document Type: Article

References (37)

1. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398-407.
2. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007;91-6.
3. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216-23.
4. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-83.
5. Noubouossie DF, Lê PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, Demulder A. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol 2012;87:145-9.
6. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011;86:123-54.
7. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
8. Lewis DA, Nyska A, Potti A, Hoke HA, Klemp KF, Ward SM, Peddada SD, Wu J, Ortel TL. Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. Thromb Res 2006;118:747-53.
9. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, Strayhorn D, Hinderliter A, Key NS. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One 2012;7:e29786.
10. Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
11. Verlhac S. Transcranial Doppler in children. Pediatr Radiol 2011;41(Suppl 1):S153-65.
12. Filippin L, Debaugnies F, Noubouossié D, Lê PQ, Ferster A, Demulder A. Thrombin generation test: establishment of reference values according to age and tissue factor concentration is essential before implementation into the laboratory. Rev Med Brux 2011;32:69-73.
13. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006;95:772-5.
14. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
15. Kwiatkowski JL, Zimmerman RA, Pollock AN, Seto W, Smith-Whitley K, Shults J, Blackwood-Chirchir A, Ohene-Frempong K. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009;146:300-5.
16. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011;117:1130-40.
17. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 1978;9:45-52.
18. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 1986;20:684-90.
19. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, Thompson W, Hess D. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-10.
20. Shah N, Thornburg C, Telen MJ, Ortel TL. Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res 2012;130:e241-5.
21. Hsieh H-L, Tung W-H, Wu C-Y, Wang H-H, Lin C-C, Wang T-S, Yang C-M. Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009;29:1594-601.
22. Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, O'Sullivan J, Caplice N. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res 2009;105:214-8.
23. Noubouossie DCF, Lê P-Q, Rozen L, Debaugnies F, Ferster A, Demulder A. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 2012;130:259-64.
24. Gerotziafas GT, Van Dreden P, Chaari M, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 2012;107:1044-52.
25. Van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, Van Doormaal FF, Meijers JCM, Biemond BJ. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009;94:1513-9.
26. Setty BNY, Key NS, Rao AK, Gayen-Betal S, Krishnan S, Dampier CD, Stuart MJ. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol 2012;157:370-80.
27. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
28. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-4.
29. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, Fondu P, Toppet M, Sariban E. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88:1960-4.
30. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
31. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987;69:109-16.
32. Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 2000;96:1119-24.
33. Colella MP, De Paula EV, Conran N, Machado-Neto JA, Annicchino-Bizzacchi JM, Costa FF, Saad STO, Traina F. Hydroxyurea is associated with reduction of hypercoagulability markers in sickle cell anemia [Internet]. J Thromb Haemost 2012;10:1967-70.
34. Spronk HMH, Dielis AWJH, Panova-Noeva M, Van Oerle R, Govers-Riemslag JWP, Hamulyák K, Falanga A, Cate HT. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? Thromb Haemost 2009;101:1156-62.
35. Van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008;19:183-9.
36. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renné T, Ten Cate H, Spronk HMH. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012;10:1355-62.
37. Dargaud Y, Luddington R, Gray E, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007;139:303-9.